跳至主要内容
临床试验/JPRN-UMIN000010093
JPRN-UMIN000010093已完成未知

The Effect of Alogliptin on Cardiovascular Disease in Patients with Acute Coronary Syndromes - The Effect of Alogliptin on Cardiovascular Disease in Patients with Acute Coronary Syndromes

Yokohama City University Medical Center0 个研究点目标入组 80 人开始时间: 2013年2月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
80

研究概览

简要总结

Alogliptin treatment, independently of glycemic and lipid status, resulted in significant plaque regression and stabilization in non-culprit coronary lesions in patients with acute coronary syndrome and mild dysglycemia. Atherosclerosis. 2022 Nov;360:1-7.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients with cancer, severe infectious disease, traumatic disease or hypersensitivity to test drug, and patients who are judged by the principal or other investigator to be ineligible for enrollment in the study. 2) Patients pretreated with DPP-4 inhibitors or GLP-1 analogues. 3) Target PCI lesion is graft stenosis or in-stent restenosis. 4) Patients who had undergone previous PCI for the lesion under investigation. 5) Patients with cardiogenic shock 6) Patients on cyclosporine therapy 7) Patients with liver dysfunction (ALT[GPT] >= 100IU), biliary obstruction and/or defective hepatic metabolism: acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, hepatic carcinoma and/or icterus. 8) Pregnant and possibly pregnant women, lactating women. 9) Patients on maintenance dialysis

研究者

相似试验